15 patents
Utility
Protease Inhibitors As Antivirals
12 Oct 23
Long Mao, Xiao Xu, Namir Shaabani, Can Jin
Filed: 15 Jun 23
Utility
Protease inhibitors as antivirals
12 Sep 23
Long Mao, Xiao Xu, Namir Shaabani, Can Jin
Filed: 1 Jun 22
Utility
Heterocyclic compounds and uses as anticancer agents
28 Mar 23
The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
Filed: 24 Aug 20
Utility
Protease Inhibitors As Antivirals
26 Jan 23
Long Mao, Xiao Xu, Namir Shaabani, Can Jin
Filed: 1 Jun 22
Utility
Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide
15 Nov 22
Long Mao, Jia Liu, Yile Chen, Yuning Hua, Kongen Dai, Yimei Bao, Bojie Weng, Xi-aopeng Mo, Jian Wu, Xiao Xu, Wanhong Xu, Xiaobo Wang
Filed: 7 Apr 17
Utility
Process for Manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and Formulations Thereof
7 Oct 21
The invention relates to solid forms of certain N-(pyrimidinyloxy)acrylamide derivatives that are useful in the treatment of proliferation and immunological disorders and other diseases related to the dysregulation of kinases including EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3 (D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK.
Long MAO, Jia LIU, Yile CHEN, Yuning HUA, Kunhua DONG, Liang CHEN, Bojie WENG, Xiaopeng MO, Kongen DAI, Yimei BAO, Jian WU, Bin LIANG, Guanglin ZHOU, Zhen WANG
Filed: 9 Aug 18
Utility
Pharmaceutical Salts, Physical Forms, and Compositions of Pyrrolopyrimidine Kinase Inhibitors, and Methods of Making Same
30 Sep 21
Disclosed methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC AND TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.
Long MAO, Jia LIU, Yile CHEN, Yuning HUA, Kongen DAI, Yimei BAO, Bojie WENG, Xi-aopeng MO, Jian WU, Xiao XU, Wanhong XU, Xiaobo WANG
Filed: 7 Apr 17
Utility
EGFR modulators and uses thereof
18 May 21
The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
Filed: 30 Sep 19
Utility
Heterocyclic Compounds and Uses As Anticancer Agents
8 Apr 21
The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
Xiao XU, Xiaobo WANG, Long MAO, Li ZHAO, Biao XI
Filed: 24 Aug 20
Utility
Heterocyclic compounds and uses as anticancer agents
12 Oct 20
The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
Filed: 11 Jan 13
Utility
Novel Egfr Modulators and Uses Thereof
29 Apr 20
The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
Xiao XU, Xiaobo WANG, Long MAO, Li ZHAO, Biao XI
Filed: 29 Sep 19
Utility
Pyrrolopyrimidine compounds as inhibitors of protein kinases
23 Mar 20
The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.
Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
Filed: 16 Feb 17
Utility
Heterocyclic compounds and uses thereof
17 Feb 20
The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.
Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
Filed: 28 Jan 18
Utility
Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
13 Jan 20
Provided are methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3 (D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.
Long Mao, Jia Liu, Yile Chen, Yuning Hua, Kongen Dai, Yimei Bao, Bojie Weng, Xiaopeng Mo, Jian Wu, Xiao Xu, Wanhong Xu, Xiaobo Wang
Filed: 29 Jun 16
Utility
EGFR modulators and uses thereof
21 Oct 19
The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
Filed: 17 Sep 17
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first